Impact of reduced human papillomavirus vaccination coverage rates due to COVID-19 in the United States: A model based analysis

被引：76

作者：

Daniels, Vincent ^{[1
]}

Saxena, Kunal ^{[1
]}

Roberts, Craig ^{[1
]}

Kothari, Smita ^{[1
]}

Corman, Shelby ^{[2
]}

Yao, Lixia ^{[1
]}

Niccolai, Linda ^{[3
]}

机构：

[1] Merck & Co Inc, Ctr Observat & Real World Evidence, 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA

[2] OPEN Hlth, 4350 East West Highway Suite 1100, Bethesda, MD 20814 USA

[3] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, POB 208034,60 Coll St, New Haven, CT 06520 USA

来源：

VACCINE | 2021年 / 39卷 / 20期

关键词：

COVID-19; 9-valent human papillomavirus (HPV) vaccine; United States; Genital warts; Cervical cancer; HPV;

D O I：

10.1016/j.vaccine.2021.04.003

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The coronavirus disease 2019 (COVID-19) pandemic has significantly affected utilization of preventative health care, including vaccines. We aimed to assess HPV vaccination rates during the pandemic, and conduct a simulation model-based analysis to estimate the impact of current coverage and future pandemic recovery scenarios on disease outcomes. The model population included females and males of all ages in the US. The model compares pre-COVID vaccine uptake to 3 reduced coverage scenarios with varying recovery speed. Vaccine coverage was obtained from Truven Marketscan (TM). Substantially reduced coverage between March-August 2020 was observed compared to 2018-2019. The model predicted that 130,853 to 213,926 additional cases of genital warts; 22,503 to 48,157 cases of CIN1; 48,682 to 110,192 cases of CIN2/3; and 2,882 to 6,487 cases of cervical cancer will occur over the next 100 years, compared to status quo. Providers should plan efforts to recover HPV vaccination and minimize potential long-term consequences. (C) 2021 The Authors. Published by Elsevier Ltd.

引用

页码：2731 / 2735

页数：5

共 14 条

[1]

[Anonymous], 2019, IBM MARKETSCAN RES D

[2]

Bramer CA, 2020, MMWR-MORBID MORTAL W, V69, P630, DOI [10.15585/mmwr.mm6920e1, 10.1111/ajt.16112]

[3]

Bureau USC, US WORLD POP CLOCK

[4]

Centers for Disease Control and Prevention, 2019 AD HUM PAP HPV

[5] Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States [J].

Daniels, Vincent ;

Prabhu, Vimalanand S. ;

Palmer, Cody ;

Samant, Salome ;

Kothari, Smita ;

Roberts, Craig ;

Elbasha, Elamin .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (07) :1943-1951

[6] A Multi-Type HPV Transmission Model [J].

Elbasha, Elamin H. ;

Dasbach, Erik J. ;

Insinga, Ralph P. .

BULLETIN OF MATHEMATICAL BIOLOGY, 2008, 70 (08) :2126-2176

[7] Model for assessing human papillomavirus vaccination strategies [J].

Elbasha, Elamin H. ;

Dasbach, Erik J. ;

Insinga, Ralph P. .

EMERGING INFECTIOUS DISEASES, 2007, 13 (01) :28-41

[8] Impact of vaccinating boys and men against HPV in the United States [J].

Elbasha, Elamin H. ;

Dasbach, Erik J. .

VACCINE, 2010, 28 (42) :6858-6867

[9] Age-Based Programs for Vaccination against HPV [J].

Elbasha, Elamin H. ;

Dasbach, Erik J. ;

Insinga, Ralph P. ;

Haupt, Richard M. ;

Barr, Eliav .

VALUE IN HEALTH, 2009, 12 (05) :697-707

[10]

Epic Health Research Network, DEL CANC SCREEN 2 LO

← 1 2 →